- Home
- HGTY vs PHVS Comparison
HGTY vs PHVS Comparison
Compare HGTY & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGTY
- PHVS
- Stock Information
- Founded
- HGTY 1984
- PHVS 2015
- Country
- HGTY United States
- PHVS Switzerland
- Employees
- HGTY N/A
- PHVS N/A
- Industry
- HGTY Specialty Insurers
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- HGTY Finance
- PHVS Health Care
- Exchange
- HGTY Nasdaq
- PHVS Nasdaq
- Market Cap
- HGTY 820.4M
- PHVS 909.5M
- IPO Year
- HGTY N/A
- PHVS 2021
- Fundamental
- Price
- HGTY $9.72
- PHVS $16.60
- Analyst Decision
- HGTY Hold
- PHVS Strong Buy
- Analyst Count
- HGTY 3
- PHVS 5
- Target Price
- HGTY $10.50
- PHVS $39.20
- AVG Volume (30 Days)
- HGTY 78.2K
- PHVS 59.4K
- Earning Date
- HGTY 05-07-2025
- PHVS 05-13-2025
- Dividend Yield
- HGTY N/A
- PHVS N/A
- EPS Growth
- HGTY 124.60
- PHVS N/A
- EPS
- HGTY 0.20
- PHVS N/A
- Revenue
- HGTY $1,247,923,000.00
- PHVS N/A
- Revenue This Year
- HGTY $16.08
- PHVS N/A
- Revenue Next Year
- HGTY $16.80
- PHVS N/A
- P/E Ratio
- HGTY $47.75
- PHVS N/A
- Revenue Growth
- HGTY 18.45
- PHVS N/A
- 52 Week Low
- HGTY $8.03
- PHVS $11.51
- 52 Week High
- HGTY $12.35
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- HGTY 58.99
- PHVS 52.79
- Support Level
- HGTY $9.08
- PHVS $15.46
- Resistance Level
- HGTY $9.99
- PHVS $16.50
- Average True Range (ATR)
- HGTY 0.36
- PHVS 1.04
- MACD
- HGTY 0.00
- PHVS -0.10
- Stochastic Oscillator
- HGTY 70.33
- PHVS 75.33
About HGTY Hagerty Inc.
Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically it serves Europe, Canada, and the United States.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.